Lanreotide

Overview

Lanreotide is a synthetic cyclic octapeptide analog of the endogenous hormone Somatostatin (somatotropin release-inhibiting factor). Developed by Ipsen and marketed as Somatuline Depot (US) or Somatuline Autogel (EU), it was approved by the FDA in 2007 for the long-term treatment of acromegaly in patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. In 2014, the FDA expanded its indication to include the treatment of unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Like Octreotide, lanreotide mimics the inhibitory actions of native somatostatin but with substantially improved pharmacokinetic properties. Native somatostatin has a plasma half-life of only 1-3 minutes, making it impractical for chronic therapy. Lanreotide achieves a functional half-life of approximately 23-30 days when administered as a supersaturated depot formulation, enabling once-monthly dosing.

The peptide was designed by incorporating D-amino acids and reducing the ring size to enhance metabolic stability while retaining somatostatin receptor binding activity. Lanreotide preferentially binds somatostatin receptor subtypes 2 (SSTR2) and 5 (SSTR5), the principal mediators of growth hormone (GH) suppression and antiproliferative signaling.

Structure and Pharmacology

Molecular characteristics:

• Sequence: D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 (cyclic via Cys2-Cys7 disulfide)
• Molecular weight: 1,096.3 Da
• Molecular formula: C54H69N11O10S2
• Key features: Cyclic octapeptide with one Disulfide bond, D-amino acid substitutions at positions 1 and 4, C-terminal amidation

Somatostatin Receptor Binding

Lanreotide exhibits the following receptor binding profile:

This receptor selectivity profile is similar to Octreotide but with somewhat higher affinity for SSTR5, which may contribute to differential effects on insulin and glucagon secretion in some clinical contexts.

Mechanism of Action

Lanreotide exerts its therapeutic effects through multiple mechanisms:

Hormonal suppression:

• Binds SSTR2 and SSTR5 on anterior pituitary somatotroph cells, inhibiting growth hormone release via Gi-protein-coupled suppression of cAMP and calcium influx
• Reduces circulating insulin-like growth factor 1 (IGF-1) levels secondary to GH suppression
• Inhibits secretion of multiple gastrointestinal hormones including gastrin, Cholecystokinin, Secretin, vasoactive intestinal peptide, and pancreatic polypeptide

Antiproliferative effects:

• Direct cell cycle arrest in tumor cells expressing SSTR2 via activation of protein tyrosine phosphatases (SHP-1, SHP-2)
• Induction of Apoptosis through SSTR3-mediated pathways at higher concentrations
• Indirect antitumor effects via suppression of angiogenic growth factors (VEGF) and modulation of the tumor microenvironment

Gastrointestinal effects:

• Reduces splanchnic blood flow
• Decreases pancreatic exocrine secretion
• Slows gastrointestinal motility and reduces gallbladder contractility

Formulation and Administration

The Somatuline Depot formulation is a supersaturated aqueous solution of lanreotide acetate that spontaneously forms a semi-solid depot upon deep subcutaneous injection. This depot formulation is unique among somatostatin analogs:

• Concentration: 60 mg, 90 mg, or 120 mg in prefilled syringes
• Route: Deep subcutaneous injection in the superior external quadrant of the buttock
• Frequency: Every 28 days (extended to every 42-56 days in some stabilized patients)
• Self-administration: The prefilled syringe with automatic needle insertion system allows trained patients or caregivers to administer injections at home

The depot forms a precipitate at the injection site that slowly dissolves over 4-5 weeks, providing sustained plasma concentrations with Cmax achieved at approximately day 1 and steady-state levels maintained between days 7-28.

Clinical Applications

Acromegaly

Acromegaly results from excessive GH secretion, typically by a pituitary adenoma. Lanreotide reduces GH and IGF-1 levels to within normal ranges in approximately 50-70% of patients. It may be used as:

• Primary therapy: When surgery is contraindicated or declined, or while awaiting the effects of radiation therapy
• Adjunctive therapy: Following incomplete surgical resection when GH/IGF-1 levels remain elevated
• Pre-surgical treatment: To reduce tumor volume and improve surgical outcomes in some patients with macroadenomas

Dose titration is guided by GH and IGF-1 levels, with the goal of achieving age- and sex-normalized IGF-1 concentrations.

Gastroenteropancreatic Neuroendocrine Tumors

The CLARINET trial (Controlled study of Lanreotide Antiproliferative Response in NETs) demonstrated that lanreotide 120 mg every 28 days significantly prolonged progression-free survival in patients with advanced GEP-NETs compared to placebo. This antiproliferative effect was observed regardless of hepatic tumor burden or primary tumor site (pancreas, midgut, hindgut, or unknown).

Additional Applications

• Carcinoid syndrome: Symptomatic relief of diarrhea and flushing associated with functional neuroendocrine tumors
• Thyrotropinomas: Suppression of TSH-secreting pituitary adenomas
• Polycystic liver and kidney disease: Investigated for reduction of hepatic and renal cyst volume

Pharmacokinetics

Safety Profile

Lanreotide is generally well tolerated with a predictable adverse effect profile consistent with somatostatin receptor activation:

• Gastrointestinal: Diarrhea (26-37%), abdominal pain (7-19%), nausea (5-11%), constipation in some patients
• Cholelithiasis: Gallstone formation occurs in 14-30% of patients due to reduced gallbladder motility; ultrasonographic monitoring is recommended
• Injection site reactions: Induration, pain, or nodule at the depot site (5-22%)
• Metabolic: Hyperglycemia or hypoglycemia due to effects on insulin and glucagon secretion; glucose monitoring is warranted, especially in diabetic patients
• Cardiovascular: Sinus bradycardia (3-8%), generally asymptomatic

Serious adverse effects are uncommon. Anaphylaxis and serious hypersensitivity reactions have been reported rarely.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines. Lanreotide (Somatuline Depot) is an FDA-approved somatostatin analog. Always consult a qualified healthcare professional.

Administration notes: Supplied as a prefilled syringe with automatic needle insertion for deep subcutaneous injection. Trained patients or caregivers can administer at home. Dose adjustments in acromegaly are guided by GH and age/sex-normalized IGF-1 levels. In stabilized acromegaly patients, the injection interval may be extended to every 6-8 weeks. Monitor gallbladder by ultrasound periodically.

Comparison with Other Somatostatin Analogs

Lanreotide, Octreotide, and Pasireotide represent three generations of somatostatin analogs with distinct receptor binding profiles and clinical applications. Lanreotide and octreotide share similar SSTR2-preferring profiles, while pasireotide has broader multi-receptor activity. The choice among these agents is guided by disease type, prior treatment response, and individual tolerability.

The development of somatostatin analogs demonstrates how iterative medicinal chemistry applied to short, unstable endogenous peptides can yield clinically transformative long-acting therapeutics.